Optimized Determination of Plasma Prokallikrein on a Hitachi 705 Analyser by Adam, A. et al.
Adam, Azzouzi, Boulanger, Ers, Albert, Damas and Faymonville: Optimized determination of plasma prokallikrein 203
J. Clin. Chem. Clin. Biochem.
Vol. 23, 1985, pp. 203-207
Optimized Determination of Plasma Prokallikrein
on a Hitachi 705 Analyser
By A. Adam, M. Azzouzi, J. Boulanger, P. Ers
Laboratoire de Biologie Clinique, C. H. de Sainte Odet Baconfoy, Belgium
Laboratoire de Radioimmunologie (Prof. P. Franchimont), Universite de Liege, Belgium
A. Albert
Laboratoire de Chimie Medicale (Prof. C. Heusghem), Universite de Liege, Belgium
J. Damas
Institut de Physiologie normale et pathologique (Prof. J. Lecomte), Universite de Liege, Belgium and
M. E. Faymonville
Service d'Anesthesiologie (Prof. M. Lamy), Universite de Liege, Belgium
(Received July 19/October 22, 1984))
Summary: Manual determination of plasma prokallikrein using a chromogenic Substrate is tedious. We
describe the optimal conditions of enzymatic quantification by a fully automated method enabling rapid
aväilability of the resülts and an easier estimation of this interesting compound in clinical chemistry.
Optimierte Bestimmung von Prokallikrein im Plasma mit dem Hitachi 705 Analyser
Zusammenfassung: Die manuelle Bestimmung von Prokallikrein im Plasma mit einem chromogenen Substrat
ist anspruchsvoll. Wir beschreiben die optimalen Bedingungen für die enzymatische Bestimmung als Kallikrein
mit einer vollautomatisierten Methode, deren Ergebnisse kurzfristig erhalten werden können und die diesen
interessanten Bestandteil des Plasmas einer einfacheren Bestimmung zugänglich macht.
However, this quantification requires a prior "in
Introduction
 vitro„ activation ^ two step procedure and the
Hageman factor (factor XII) is activated by contact rapid inactivation of plasma prokallikrein by
with negatively charged surfaces (e. g. dextran antiproteases make difficult the application of this
sulph^te, ellagic acid). The cleavage products of fac- manual procedure in routine clinical and chemical
tor XII activate plasma prokallikrein to plasma analysis. Here, we describe a fully automated method
kallikrein. The latter will liberate preferentially for the quantification of human plasma prokallikrein.
bradykinin from high molecular weight kininogen. After analytical validation and reference value de-
The aväilability of chromogenic and fluorogenic sub- terminations, we first applied this method to the
strates (1) has made possible the study of the study of patients undergoing aortocoronary bypass
physiopathological significance of this protease. grafts under nonpulsatil cardiopulmonary bypass.
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Material and Methods
Blood sampl ing
After elimination of the first milliliter to remove "endogenous"
tissue activator, blood is collected by venipuncture in 0.1
mol/i sodium citrate s anticoagulant (one part sodium citrate
to nine parts blood) in a polystyrene tube. The sample is
centrifuged (15 °C 10 min, 1500g) within l h after collection.
The supernatant is removed with a plastic pipette. The plasma
can be stored at — 30 °C and plasma prokallikrein detennined
within one month.
The effect of heparin (0-10 U/rnl) (Calparin R che, Basel,
Switzerland) and its antagonists (pro tarn ine sulphate, R che;
polybrene, Aldrich Europe, Beerse, Belgium) on plasma pro-
kallikrein measurement were tested using a plasma pool. Be-
cause l mg of polybrene or l μΐ of protamine sulphate
neutralizes 1000 units of heparin, the concentrations of protein
and coagulation factors were the same in each sample.
For this study and for the samples containing heparin, this
anticoagulant was first quantified by a thrombin time test
using titrarine (Stago, Asnieres, France) or with a chromogenic
Substrate assay (Boehringer Pharma, Mannheim, GFR).
Reagents
The chromogenic Substrate used to quantify plasma pro-
kallikrein activated to kallikrein is chromozym PK (Bz-Pro-
Phe-Arg-pNA - HC1), Mr = 679.3 (Boehringer Pharma,
Mannheim, FRG).
The incubation buffer is Imidazole/Tris 0.33 mol/1 pH 7.9,
containing NaCl 0.33 mol/1. Various activators have been
tested: dextran sulphate (Mr = 500000, Pharmacia, Upsala,
Sweden), dextran sulphate plus acetone or acetonitrile (analysis
grade, Merck, Darmstadt, FRG), cephotest (Nyegaard, Oslo,
Norway), thrombofax (Ortho Diagnostic System, New Jersey,
USA).
I n s t r u m e n t s
A model 24 spectrophotometer (Beckman Instruments, Brea,
USA) was used for the manual determination of plasma pro-
kallikrein. Fully automatic measurements were made with a
Hitachi 705 System (Naka works, Katsuba, Japan).
Procedure
The manual determination of plasma prokallikrein was per-
formed according to the original technique described by Kluft
(2). However, aqueous Solutions of dextran sulphate (25 mg/1)
containing increasing concentrations of acetone or acetonitrile
(0, 100, 200. 300, 400 ml/l) were tested s activator at four
different temperatures (4, 15, 26 and 37 °C). After adding
25 μΐ of the activator to 25 μΐ of plasma, the sample was
incubated for various time intervals ranging from 150 to 900s.
Measurement was made at 405 nm (37 °C) over 3 min.
For the automatic determination, activation and measurement
of the resulting kallikrein catalytic activity was performed at
the same temperature. We tested three kinds of activator diluted
in the incubation buffer: dextran sulphate (initial concentration:
10, 25, 50 mg/1), cephotest and thrombofax (initial dilution
100, 75 and 50 rnl/1).
Plasma (5 μΐ) was incubated with the activation mixture
(500 μΐ). Then the automatic Systems adds 60 μΐ of the Substrate
(initial concentrations of 4mmol/l). The incubation times
(6min 20s, 7min 20s, or 8min 20s) were determined by the
instrumental conditions. Afterwards the kallikrein catalytic
activity is measured by the change in absorbance per minute
(ΔΑ/min) at 415 nm.
The results were calculated by multiplying the ΔΑ/min value
by 10.865. This factor was obtained s follows:
Catalytic concentration (U/l) = — χ 0'565 X 10°
min 1040 χ 0.005
ΔΑ
min x 10.865
0.565 is the final volume, 0.005 the sample volume and 1040
the molar lineic absorbance of/?-nitroaniline.
Refefence values and clinical application
To determine the reference r nge, plasma specimens from 87
healthy adults were assayed. These subjects (20—35 years) had
neither Symptoms of inflammation nof hepatic insufficiency.
The influence of oral contraceptive (n = 46) and pregnancy
(n = 193) on plasma prokallikrein values was also tested.
The method was checked on patients (n = 5) undergoing
cardiac surgery. To exclude biochemical changes due to surgery,
we did the same tests on patients undergoing total hip re-
placement. Blood samples were collected from radial artery and
internal jugular vein; the various results were corrected for
haemodilution and were compared with the initial value by a
Student t test.
Results
Effect of various activation conditions
A comparative examination of fig re l shows that
highest values are obtained after an activation time
of at least 7 min 30 s at 4 °C with dextran sulphate
alone or in the presence of acetone (volume fraction
0.1). When higher coricentf tions of acetone are used,
the values are clearly lower.
When the activation temperature is increased to 15,
26, and finally 37 °C, the maximum value obtained
with dextfan sulphate alone or in the presence of
acetone (volume fraction 0.1) is lower and decreases
progressively with the time of activation. Howeyer,
at these temperatures the values obtained with a
volume fractior* of 0.20 acetone are more stable d r-
ing incubation. In any case, the results were similar
for acetonitrile. The lowest values were fpund after
activation with a volume fraction of 0.40 acetone,
due to protein precipitation.
Automated method
Selection of optimal assay conditions and analytical
characteristics
The values obtained at 25 and 37 °C with the three
0
 activators are shown in fig re 2. At 30 °C in-
termediate values were obtaine^ (results not shown),
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Fig. 1. Kinetics of plasma prokallikrein activation at four
temperatures using the manual method.
Activators:
dextran sulphate alone (-O-);
dextran sulphate plus acetone, volume fraction
0.1 (-Q-), 0.2 (-Π-), 0.3 (-x-), 0.4 (-Δ-)
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Fig. 2. Selection of optimal conditions for plasma prokallikrein
activation on the Hitachi 705 using two difTerent
temperatures, 25 °C (f ll lines) and 37 °C (dashed lines).
a) dextran sulphate: 25 mg/1 (-x-); 10 mg/1 (-·-)
b) cephotest 75 ml/l (-x-); 100 ml/l (-Φ-); 50 ml/l
(-0-).
c) thrombofax 75 mlA ΗΗ; 100 ml/l (-·-); 50 ml/l
(-0-)
Using dextran sulphate, the catalytic activities
decreased with the time of activation. At 50 mg/1,
no catalytic activity was obtained, due to protein
precipitati n,
With thrombofax r cephotest, the catalytic activity
after 6 min 20 s increased with temperature. At 37 °C,
the catalytic activity obtained with cephotest in-
creased with the time of activation — the maximum
being reached after 8 min 20 s, using a volume frac-
tion 0.1 of this activator in the buffer. The following
optimal conditions were selected for the continuation
of this study: 5 μΐ of plasma activated by incubation
for 8 min 20 s at 37 °C with 500 μΐ of cephotest 1/10
diluted in the incubation buffer.
The analytical characteristics are shown in table 1.
The within-run precision s well s the precision
within and between days, are excellent. The coeffi-
cient of Variation is in each case less than 5%. Using
serial dilutions of plasma with a plasma prokallikrein
value of 1000 U/l a linear relation was obtained up
to 5 U/l. This level was chosen s the limit of sensitiv-
ity of our automated method.
Tab. l. Plasma prokallikrein assay: Precision obtained with the
fully automated method.
Within run precision (n = 20)
Mean SD
(U/l) (U/l)
872 * 9
448 3
176 5
Run-to-run precision (n = 5)
Mean SD
(U/l) (U/l)
686 10
Day-io-day precision (n = 25)
Mean SD
(U/l) (U/l)
698 < 0
CV
(%)
1.03
0.66
2.84
CV
1.46
CV
2.5
The results obtained with this automated method
show an excellent correlation (r = 0.96) with those
obtained using the manual reference method (flg. 3).
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Fig. 3. Correlation between plasma prokallikrein measured s
kallikrein catalytic activities obtained with manual and
automated method. y = -13.79 H- 1.59x (n = 40).
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Figure 4 represents the levels of plasma prokallikrein
when increasing quantities of heparin (0.5 — 10 U/ml)
were added to a pool plasma. The plasma pro-
kallikrein values decrease progressively up to
4 U/ml heparin. A plateau equal to one third of the
initial value is then observed between 4 and 10 U/ml.
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Fig. 4. Effect of increasing levels of heparin (U/l) before (-O-)
and after neutralization (- -) with polybrene or pro-
tamine sulphate on plasma prokallikrein measured äs
kallikrein catalytic activities (U/l).
When equivalent quantities of polybrene or pro-
tamine sulphate are added to neutralize the heparin,
the initial value is preserved. An excess of both sub-
stances equivalent to 5 U/ml of heparin does not
interfere in the quantification of plasma pro-
kallikrein.
Reference values
The distribution of the results for healthy adults is
shown in table 2. There is no significant difference
between plasma prokallikrein values for men and
women. However, women taking oral contraceptives
and pregnant women have significantly higher plasma
prokallikrein.
Tab. 2. Reference values of plasma prokallikrein (U/l).
Group N Mean ± 1 SD Group
comparison
1 men
2 women
3 women using
oral contra-
ceptives
4 pregnant
women
35
52
46
193
732 ± 108
695 ± 112
893 ± 155
861 ± 167
t
1 vs2
2 v s 3
3 vs4
4 v s 2
1.55
7.31*
1.18
6.76*
Applicat ion of the plasma prokal l ikrein de-
terminat ion in surgery
Patients undergoing cardiac surgery receive large
doses of heparin. The levels of this anticoagulant in
plasma determined by a thrombin time test varies
between 0.5 and 5 U/ml. Quantification of plasma
prokallikrein has been achieved with and without
in vitro-neutralization of heparin by adding equal
amounts of protamine sulphate. The results are
shown in figure 5.
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Fig. 5. Variation of plasma prokallikrein measured äs
kallikrein catalytic activity (U/1) during cardiac surgery
before (—) and after (—) neutralisation of heparin.
1: presurgery, 2: anesthesia, 3: surgery, 4—8: cardio-
pulmonary bypass, 9:15 minutes after cardiopulmonary
bypass, 10: intensive care unit.
No significant difference is obServed between arteriäl
and venous prokallikrein plasma levels. After start of
anesthesia and after sternotomy, plasma prokallikrein
shows no significant changes. At the beginning of
cardiopulmonary bypass, a significant drop (p <Q.05)
in plasma prokallikrein can be observed. This
decreased plasma prokallikrein last$ üritil the limgs
are reperfused. Although the variations are more
important without neutralizätiön of heparin, the
differences are significant in both cases. During total
hip replacement no statistical Variation of plasma
prokallikrein was observed at any time during
surgery.
Discussion
Chromogenic and fluorogenic Substrates are now
commercially available (1) for enzymatic quantif-
ication öf plasma prokallikrein. We used chromozym
PK. The results obtained with the chromogenic sub-:
strate S-2302 (Kabi, Diagriöstica, Stokholm, Sweden)
are comparable (3).
 % ?'
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This enzymatic determination necessitates a prior
activation of Hageman factor by contact with nega-
tively charged sufaces. Various activators have been
described: dextran sulphate (2), ellagic acid (4) and a
preparation of high molecular weight kininogen and
Hageman factor (Kabi, S-11287).
The activated plasma kallikrein is bound to
antiproteases such äs: Cl esterase inhibitor,
antithrombin III, arproteinase inhibitor. Various ap-
proaches have been tried to diminish this interaction
during activation of plasma prokallikrein at low
temperature (1), e. g. dilution of the incubation me-
dium (4), addition of a hydrophilic organic solvent
(3) or exposure of the plasma to a hydrophobic sol-
vent (5).
With the manual determination, maximal catalytic
activities are obtained at 4 °C with dextran sulphate
alone or dextran sulphate plus acetone or acetonitrile
(volume fraction 0.1). When measurements are per-
formed at higher temperatures, acetone seems to have
a protective effect on the resulting kallikrein; its in-
hibition by various antiproteases seems to be
temperature dependent. The effect of these inhibitory
proteins is more pronounced at 25 and 37 °C. At
these temperatures, acetone has in fact two effects —
early Inhibition of activation, and later protection of
kallikrein catalytic activity.
When adapting this determination to a Hitachi 705,
plasma prokallikrein must be activated and quanti-
fied at the same temperäture. Under these optimized
conditions, the use of ellagic acid äs the activator
leads to results that are perfectly correlated with
those obtained by the reference method of Kluft (2).
The fully automated method therefore gives a reliable
measurement of plasma prokallikrein levels.
Like others, we observed that heparin lowers plasma
prokallikrein values, but heparin can be neutralized
beföre activation is started. This will be useful for
application of the assay to patients with acute in-
flammatory disease who often receive heparin. Like
ho & Statland (3), we noted no difference between
sexes. However, pregnant women and women taking
oral contraceptives had significantly higher plasma
prokallikrein values. In these two cases, the increased
plasma prokallikrein must be due to an increase in
hepatic synthesis. The extracorporeal circulation
study shows a negative influence of heparin on
kallikrein catalytic activity, but also an activation of
plasma prokallikrein during cardiopulmonary
bypass. This activation of plasma prokallikrein is
probably not due to surgery, äs can be concluded
from the results obtained in orthopedic surgery, but
probably to the contact of the blood with negatively
charged surfaces (6 — 8).
In conclusion, we have described a reliable fully au-
tomated determination of plasma prokallikrein,
which will facilitate further exploration of the
kallikrein-kininogen-kinin System in various
pathophysiological conditions (9). The application of
this method to routine clinical chemical analysis is
also described.
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